AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03727867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Description: Oral EGFR TKI begins on day 1 and continues until disease progresses.
Study NCT03727867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
Study NCT02941497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social marketing and health promotion campaign
Description: Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
Study NCT01216982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, visually identical to Lovaza
Description: Three 1g corn oil capsules/day for three months
Study NCT00850720 — intervention group
Intervention type: OTHER
Intervention: Blood draws
Description: Samples of blood to be drawn before surgery, and nine hours after surgery.
Study NCT01482949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Autologous Dendritic Cell Immunotherapy
Study NCT03615209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transauricular vagus nerve stimulation
Description: Stimulation will be performed for 150 minutes (throughout the entire OGTT).
Study NCT03615209 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transauricular sham stimulation
Description: Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
Study NCT03167216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Description: Mast cell stabilizer
Study NCT03167216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride
Description: Histamine receptor antagonist
Study NCT04441424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: 400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.
Study NCT04441424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquin with Azithromycin
Description: The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
Study NCT04441424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquin with Azithromycin
Description: The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
Study NCT01521325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amatuximab
Description: Subjects will receive one infusion of radiolabeled amatuximab.
Study NCT01058330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric training program
Description: The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
Study NCT04299802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte-Rich Platelet-Rich Plasma
Description: LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.
Study NCT04299802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Ultrasonic Tenotomy
Description: Discussed in Percutaneous Ultrasonic Tenotomy Arm section
Study NCT02814110 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Granulocyte colony-stimulating factor (Filgrastim)
Description: Drug administration
Study NCT04719936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior capsulotomy
Description: inferior capsulotomy will be conducted during posterior approach.
Study NCT04719936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior capsulotomy
Description: superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
Study NCT03478995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: GX-I7 25mg/ml/vial
Study NCT01978743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
Study NCT04327128 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LifePod
Description: The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
Study NCT04327128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifePod
Description: The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
Study NCT02606708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated intensity modulated radiation therapy (AIMRT)
Study NCT00897377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT00897377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT03450057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab with dexamethasone
Description: Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients >75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cheddar cheese
Description: The reference product is a commercial matured cheddar cheese
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cheddar cheese
Description: The reference product is a commercial matured cheddar cheese
Study NCT01880346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Powder
Description: Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blended and homogenized cheddar cheese
Description: A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Blended and homogenized cheddar cheese
Description: A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: An analog milk
Description: An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: An analog milk
Description: An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: An analog cheese
Description: This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
Study NCT03656367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: An analog cheese
Description: This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
Study NCT00510172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostacyclin, PGI2
Description: 10 ng/kg/min of epoprostenol (stable PGI2)
Study NCT00510172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCL 0,9%
Study NCT01010932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Each subject will receive one injection of Dotarem 0.2ml/kg
Study NCT01010932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOF MRA
Description: Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
Study NCT03692663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TABP EIC
Description: A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
Study NCT03692663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
Study NCT03692663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
Study NCT03976635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Mandibular Retractor
Description: The appliance will be used 18 hours per day. It can only be removed for eating meals.
Study NCT03976635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone-anchored intermaxillary traction
Description: The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
Study NCT00001703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: 0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
Study NCT03308578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Study NCT03308578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Study NCT00655551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
Study NCT00655551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
Study NCT00655551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
Study NCT01880346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Oil
Description: Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
Study NCT01855438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Donor Transplant Education
Description: The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
Study NCT01418872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic Concerts
Description: The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered.
Study NCT01418872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Concerts
Description: The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered.
Study NCT05203627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard nutritional support
Study NCT05203627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05203627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05203627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Visit
Description: Receive telehealth sessions
Study NCT00405041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement GVG 2
Description: 2.670 g/day for 14 days
Study NCT01701791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System
Study NCT02306278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: gabapentin capsules 0.3g
Study NCT02306278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin capsules
Description: vitamin B
Study NCT03644576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozanimod
Description: ozanimod
Study NCT03644576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine
Study NCT03644576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Pseudoephedrine
Study NCT03644576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ozanimod placebo
Description: ozanimod placebo
Study NCT03116113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.
Study NCT01011257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asprin
Description: asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
Study NCT01011257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 75 mg bid
Study NCT00924560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 91-day Levonorgestrel Oral Contraceptive
Description: Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily
Study NCT00924560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day Levonorgestrel Oral Contraceptive
Description: Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
Study NCT01991444 — intervention group
Intervention type: OTHER
Intervention: TAVI
Description: no Intervention planned, Observation only
Study NCT02858297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Description: Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
Study NCT02858297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: Topical corticosteroid
Study NCT02858297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: Topical corticosteroid
Study NCT01003314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine
Description: Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later
Study NCT01003314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge
Description: Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
Study NCT03466515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cells injection
Description: two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
Study NCT03580460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer delivered smoking cessation counseling
Description: 15 to 20 minute computer-delivered interactive smoking cessation counseling
Study NCT02933190 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transvaginal surgery；UAE and D&C
Description: For cesarean scar pregnancy treatment
Study NCT02378818 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Force task, preference task, discount task, learning task.
Description: Force task, preference task, discount task, learning task.
Study NCT01667510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardio Mato
Description: Soft gel capsule for oral use
Study NCT01667510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gel capsule without test material
Study NCT00117884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Study NCT03061708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: mTOR inhibitor